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Abstract
Aldosterone blockade confers substantial cardiovascular and renal protection. The effects
of aldosterone on mineralocorticoid receptors (MR) expressed in endothelial cells (EC)
within the renal vasculature have not been delineated. We hypothesized that lack of MR in
EC may be protective in renal vasculature and examined this by ablating the Nr3c2 gene in
endothelial cells (EC-MR) in mice. Blood pressure, heart rate and PAH clearance were mea-
sured using indwelling catheters in conscious mice. The role of the MR in EC on contraction
and relaxation was investigated in the renal artery and in perfused afferent arterioles. Uri-
nary sodium excretion was determined by use of metabolic cages. EC-MR transgenics had
markedly decreased MR expression in isolated aortic endothelial cells as compared to litter-
mates (WT). Blood pressure and effective renal plasma flow at baseline and following AngII
infusion was similar between groups. No differences in contraction and relaxation were
observed between WT and EC-MR KO in isolated renal arteries during baseline or following
2 or 4 weeks of AngII infusion. The constriction or dilatations of afferent arterioles between
genotypes were not different. No changes were found between the groups with respect to
urinary excretion of sodium after 4 weeks of AngII infusion, or in urinary albumin excretion
and kidney morphology. In conclusion, deletion of the EC-MR does not confer protection
towards the development of hypertension, endothelial dysfunction of renal arteries or renal
function following prolonged AngII-infusion.
Introduction
Hypertension and chronic kidney disease (CKD) are key contributors to morbidity and mor-
tality worldwide. In fact, arterial hypertension has been projected to affect as many as 1.56 bil-
lion individuals by the year 2025, while the prevalence of CKD currently ranges between
8–16% [1, 2]. Hypertension and CKD are major problems clinically, greatly increasing
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cardiovascular disease risk. As such, both hypertension and CKD associate strongly with endo-
thelial dysfunction [3–5], an adverse predictor of cardiovascular complications. Aldosterone
has been described as a key player in the pathogenesis of these disease states. Blockade of the
aldosterone-binding mineralocorticoid receptor (MR) have consistently been shown to reduce
blood pressure in hypertensive patients [6, 7] and slow the decline in kidney function observed
in individuals suffering from CKD [8, 9]. Pharmacologic blockade of the MR has protective
effects on renal function in CKD. Here, MR antagonism by spironolactone retards the devel-
opment of proteinuria in CKD patients, thereby slowing the progression of the disease [9].
The MR, encoded by the Nr3c2 gene remains central to these observations. Classically, the MR
expressed in renal tubular epithelium has been considered the primary mediator of adverse
cardiovascular sequelae, by facilitating aldosterone-induced hypertension. However, several
observations have since altered this view, including the discovery of MR expression in a variety
of cells, such as the endothelial and smooth muscle cells of conduit and resistance vessels [10–
12]. Furthermore, studies in individuals with primary aldosteronism find that patients suffer-
ing from this disease have a higher likelihood of developing adverse cardiovascular events,
than do patients with essential hypertension [13]. Moreover, primary aldosteronism has been
shown to impair renal function more severely in comparison to patients suffering from essen-
tial hypertension [14], suggesting that hypertension alone cannot account for the damage.
Aldosterone has been shown to affect vessel function via different cellular mechanisms
(reviewed in detail by [15, 16]). Rapid actions of the hormone are complex and oftentimes con-
tradictory and include inhibition of depolarization-induced vasoconstriction in afferent arteri-
oles [12], dose-dependent vasoconstriction in renal afferent and efferent arterioles [17, 18],
acute endothelium-dependent vasodilation in cerebral and mesenteric vessels [19] and inhibi-
tion of recovery from depolarization-induced vasoconstriction in mesenteric arteries [20].
Finally, different cellular mechanisms may be involved in driving the detrimental effects of
aldosterone in pathological models. This has been studied by ablating the MR specifically in
endothelial cells (EC) in targeted transgenic strains, subjected to chronic models of hyperten-
sion and endothelial dysfunction [21–23]. Overall, the conclusions from these studies suggest
that some vasculature isolated from mice deficient in EC MR (EC-MR KO) may show altered
vascular effects, however these alterations remain highly dependent on the vessels type studied
[21–23]. Most experimental pathological models studied in EC-MR KO mice, show protection
conferred by the EC MR towards endothelial dysfunction (i.e. a shift in balance between relax-
ing and contracting factors leading to altered vessel contractility) as evaluated by impairment
of acetylcholine-induced endothelial-dependent vasodilation [21–23]. Moreover, some but not
all studies of vessels from EC-MR KO mice in models of hypertension or endothelial dysfunc-
tion show a decreased contractility in response to constrictors, in line with a protective effect
of Nr3c2 gene ablation in endothelial cells [21–23]. For instance, Mueller et al, found that the
EC-MR KO show decreased constriction of the coronary arterioles specifically, in response to
the thromboxane agonist U46619, which is most evident following AngII-induced hyperten-
sion [23]. Thus, the varying protective effects of MR deletion in EC’s are observed during mod-
els of hypertension or endothelial dysfunction, depends on the vessel type being investigated
[21–23]. The MR is also expressed in the endothelium of various segments of the renal vascula-
ture [10, 12]. However, the effect of MR deletion in EC on vessel reactivity and function in
renal vasculature in chronic models of hypertension and endothelial dysfunction has not been
investigated. Accordingly, we hypothesized that lack of MR in EC’s may be protective for the
renal vasculature.
While the benefits of pharmacological MR blockade on renal function and associated car-
diovascular outcomes have been well described, it remains unclear how the MR in EC influ-
ences renal conduit and resistance vessel function in basal states and pathological conditions
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of hypertension and endothelial dysfunction. Given the essential role of the renal vasculature
in maintaining adequate renal function and hemodynamics, coupled with the well-described
role of the MR in protecting vessel function in chronic disease models [12, 24, 25], we aimed
to delineate in detail the effects of MR deletion in the EC upon renal vessel reactivity, blood
pressure, renal hemodynamics, and Na+ excretion rates during various durations of angioten-
sin II (AngII) infusion as experimental models for hypertension and endothelial dysfunction.
Methods
Transgenic animal models
Mice with a floxed exon 3 in the Nr3c2 gene encoding the MR have been described in detail
previously [26] and generously provided by Professors Stefan Berger and Gu¨nther Schu¨tz
(DKFZ, Heidelberg, Germany). The MR floxed mice were backcrossed from a C57BL/6 back-
ground onto an FVB/N background for a minimum of 6 generations. Mice expressing the
Tie2-Cre transgene (FVB-Tg(Tek-cre)2352Rwng/J) were generously provided by Professor
Rong Wang (UCSF, San Francisco, USA) and has been described elsewhere [27]. Intercrosses
between Nr3c2flox/flox and Nr3c2flox/flox;Tie2-Cre were used to generate mice with selective
Tie2-Cre dependent endothelial excision of the floxed Nr3c2 gene (EC-MR KO), while Tie2-
Cre negative littermates were designated as wildtypes (WT). To evaluate Tie2 promoter driven
Cre excision efficiency, LacZ/eGFP reporter mice (Z/EG) that express eGFP when Cre is active
were crossed with Tie2-Cre transgenics mice [28]. All animal experiments were conducted in
accordance with Danish Law under the animal experimental permits 2015-15-0201-00798,
2015-15-0201-00479 and 2012-15-2934-00526. Experimental procedures performed at the
Toronto Center for Phenogenomics were approved by the Animal Care Committee and were
conducted in accordance with guidelines established by the Canadian Council on Animal
Care.
Enrichment of endothelial cells from mouse aorta and vessel dissection
Endothelial cells were isolated essentially as described in detail previously [29]. In brief, mice
were anesthetized using 100 mg/kg ketamine (Ketalar) and 10 mg/kg xylazine. The thoracic
aorta was cut near the transition to the abdominal cavity and the left ventricle perfused with
heparin (1000 IU/ml). A needle was inserted into the proximal part of the aorta and ligated
with silk thread. After rinsing with DMEM, the opposing side was ligated and filled with
DMEM containing Collagenase type II solution (2mg/ml). After incubation at 37˚C for 45
minutes, the collagenase solution was rinsed out, pelleted by centrifugation and stored at
-80˚C for subsequent analysis.
To obtain tissue for RNA expression analysis of thoracic aorta, renal and mesenteric arter-
ies, EC-MR KO and WT littermates were anesthetized as described above and perfused with
30 ml of PBS trough the left ventricle. After vessels isolation, the surrounding fat and connec-
tive tissue was dissected off under a stereoscopic microscope and the samples stored at -80˚C
pending RNA extraction.
Measurement of blood pressure and effective renal plasma flow
Measurements of blood pressure, heart rate and para-aminohippuric acid (PAH) clearance
was done as described previously with modifications [30–32]. In brief, EC-MR KO and WT lit-
termates were anesthetized using 100 mg/kg ketamine and 10 mg/kg xylazine. Measurements
of mean arterial pressure and infusion of drugs was done simultaneously by implantation of
micro-renathane tip based cathethers connected to polyethylene tubing into both the femoral
Mineralocorticoid receptors in renal vasculature
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artery and vein, respectively. The arterial catheter was connected to a pressure transducer
(Fo¨hr Medical Instruments, Hessen, Germany) for continuous measurements of mean arterial
pressure (MAP) and heart rate (HR). From there, the catheters were drawn subcutaneously
and exteriorized via the neck, where they were attached to a swivel system (Instech Laborato-
ries, PA, USA) allowing free movement of the animals during recordings in an unstressed
environment. The catheters were filled with heparin solution (100 IU/ml) in isotonic glucose.
For analgesic pain relief, mice received subcutaneous injections of 3.75 mg/kg Temgesic
(buprenorphinum) post-operatively. After a recovery period (5 days), continuous measure-
ments of MAP and HR were recorded using LabView data acquisition software (National
Instruments, Austin, TX). Infusion of AngII was done in two sets of experiments, each con-
taining EC-MR KO mice and WT mice. The infusion rate was 10 μl/h. One experimental setup
utilized a high dose of AngII (100 ng/kg/min intravenously) and another with a lower dose (60
ng/kg/min intravenously). AngII infusions commenced after a period of measuring baseline
MAP and HR and until the end of the experiment.
PAH clearance was measured at baseline and during the last 24hrs of AngII infusion in the
experimental group of EC-MR KO mice and WT mice receiving 60 ng AngII/kg/min to esti-
mate effective renal plasma flow. 20% PAH (Merck) in saline was infused continuously for 24
hours allowing the clearance to reach steady state before a blood sample (100 μl) was drawn.
Blood samples were collected in EDTA tubes and plasma was isolated by centrifugation.
Measurements of PAH in plasma were done by a colorimetric reaction with dimethylamino-
cinnamaldehyde solution in an acidic environment. After 15–30 minutes of incubation, the
intensity of the light was measured at 545 nm. Renal plasma flow was calculated as the infusion
rate of PAH divided by the plasma concentration of PAH at steady state [32].
Implantation of osmotic minipumps and AngII infusion
AngII (A9525, Sigma-Aldrich) was infused at a dose of 1000 ng/kg/min using osmotic mini-
pumps (#2004, Alzet, Cupertino, CA, USA) for up to 4 weeks. The pumps were implanted sub-
cutaneously under isoflurane inhalation anesthesia and post-operative pain relief was given in
the form of Temgesic (3.75 mg/kg).
Isometric force measurements of the renal artery
The role of the MR in EC on contraction and relaxation was investigated in the renal artery of
EC-MR KO mice and WT mice at baseline or after 2 or 4 weeks of AngII infusion. Animals
were subjected to continuous infusion of AngII using osmotic minipumps as described above.
Mice were killed by cervical dislocation. Renal arteries were isolated under microscope and
mounted in a Mulvany wire myograph (model 610M, Danish Myo Technology, Aarhus, Den-
mark) to measure isometric force (LabChart, AD Instruments, Colorado Springs, CO, USA).
The renal arteries were incubated in physiologic saline solution (PSS, NaCl 115 mM, NaHCO3
25 mM, MgSO4 1.2 mM, K2HPO4 2.5 mM, CaCl2 1.3 mM, glucose 5.5 mM, and HEPES 10
mM) at 37˚C, which was buffered with 5% CO2 in air and allowed to equilibrate for 20 minutes
before experiments began. Viability of the vascular smooth muscle and endothelium was tested
with phenylephrine (10−5 M) and acetylcholine (10−7 M), respectively. KCl (60 mM) was used
to examine the maximal contraction, and phentolamine (10−5 M) was added 5 minutes prior
to and during KCl to prevent depolarization induced by α-adrenergic activity. Contractility of
the renal artery was determined using increasing concentrations of the thromboxane analog
U46619 (starting from 2x10-9 M to 10−8 M). The endothelium-derived relaxation was investi-
gated by precontraction of the arteries to 70% of the maximal contraction with U46619, and
thereafter relaxing the arteries with increasing concentrations of acetylcholine (from 10−9 M to
Mineralocorticoid receptors in renal vasculature
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10−6 M). Endothelium-independent relaxation was tested by contracting the arteries to 70% of
the maximal contraction with U46619, and thereafter relaxing the arteries with increasing con-
centrations of sodium nitroprusside, a NO donor (10−8 M to 10−5 M). Percent relaxations to
acetylcholine and sodium nitroprusside were calculated, respectively, by:
DForce½Ach
DForce70% contraction
 100%
DForce½SNP
DForce70% contraction
 100%
Determination of contractile changes in afferent arterioles
After cervical dislocation, kidneys from EC-MR KO mice and WT littermates were removed
and cortical afferent arterioles isolated by microdissection as described in detail previously
[33]. In brief, the isolated arteriole was placed in a temperature-controlled chamber (Warner)
set at 37˚C covered with DMEM-F-12 media with 0.1% BSA and maintained at 5% CO2 in air.
Perfusion of the arteriole was accomplished by placement of the vessel inside a holding pipette
and subsequent cannulation of the arteriole by insertion of a perfusion pipette. The arteriole
was opened by applying increasing perfusion pressure. Changes in luminal diameter were
recorded on an inverted microscope (Olympus) at the portion of the arteriole being most
responsive to application of KCl. After equilibration, vessel viability was tested by application
of a 100 mM K+ solution (45 mM NaCl, 70 mM KCl, 25 mM NaHCO3, 1.2 mM MgSO4, 2.5
mM K2HPO4, 1.3 mM CaCl2, 5.5 mM glucose, and 10 mM HEPES equilibrated with 5% CO2
in air, pH = 7.4) with 0.1% in the bath and 1% BSA in the luminal perfusate) in the presence of
phentolamine (10−5 mol/L). The contractile response to U46619 (thromboxane analogue) was
also tested in afferent arterioles. Finally the vessel was constricted to U46619 for tree minutes
to ensure a stable constriction and then the endothelial response was tested with increasing
concentrations of acetylcholine (10−8 M to 10−5 M). The secondary dilatory responses were
calculated by the formula below, as described previously [34]:
ðDiameterstart   ContrationmaksimumÞ   ðDiameterstart   Contration60secondsÞ
Diameterstart   Contractionmaksimum
Metabolic cage experiments
EC-MR KO mice and WT littermates were placed individually in metabolic cages. The animals
were undergoing AngII infusion by osmotic minipumps as detailed above. Measurements
were made on the 24 hour urine samples and blood collected on day 28, after insertion of the
minipumps. Animals were housed in a temperature-controlled environment with average
ambient temperature of 24.5˚C degrees and relative humidity of 50%. During the course of the
experiment, mice were allowed free access to food and water. EC-MR KO mice and WT were
maintained on a standard rodent diet (Altromin #1324) containing 3.3% agar and added water
content in the ratio of 1:1.6 of food to water. Prior to the measurements, mice were allowed
several days to acclimatize to the metabolic cages.
Measurements of electrolytes and creatinine
Creatinine in urine and blood was determined using a colorimetric assay (ABX Pentra Creati-
nine 120 CP kit, Horiba ABX SAS, Montpellier, France) according to the manufacturer’s
instructions. Na+ and K+ were determined by flame photometry (model IL 943, Instrumenta-
tion Laboratory, Lexington, MA). Albumin was measured according to the manufacturer’s
Mineralocorticoid receptors in renal vasculature
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instructions using the Mouse Albumin ELISA Quantitation kit (Bethyl Laboratories, Inc.,
Montgomery, USA).
Determination of Nr3c2 gene excision and expression by PCR and semi-
quantitative PCR
RNA was isolated from vascular beds or aortic endothelial cells from EC-MR KO mice and
WT littermates. In brief, total RNA was extracted using TRIzol Reagent (Invitrogen, Carlsbad,
CA, USA) and reverse transcribed into cDNA using iScript cDNA Synthesis Kit (Bio-Rad,
Copenhagen, Denmark). RNA used for semi-quantitiative PCR analysis was subjected to
DNase treatment (Fermentas) prior to cDNA synthesis. The following primes spanning exon
2–3 of the Nr3c2 gene were utilized Nr3c2 F: CTAGGAGAAGTGATGGGTACC and Nr3c2 R:
GAAGGTCTTGAGGATCCAGTAG and mixed with iQ SYBR Green Supermix (Bio-Rad) and
run on a Stratagene Mx3000 (AH Diagnostics, Aarhus, Denmark) for semi-quantitative assess-
ment of Nr3c2 mRNA abundance.
Primers placed in exon 2 and exon 4 of the Nr3c2 gene were used to evaluate Tie2-Cre
dependent excision of the exon 3 in various vascular beds by regular PCR using the following
primer sequences Nr3c2 E2 F2: CGGTCCTAGAGTACATTCCAG, Nr3c2 E4 R2: CTGCAGGCAG
GACAGTTCTTTC. The resulting PCR products were separated on agarose gels and visualized
using Gel Red-Nucleic Acid Stain (Biotium).
Sectioning of tissue for immunohistochemical staining
Kidneys isolated from WT and EC-MR mice were immersion fixed for 3 hours in 10% forma-
lin and stored in PBS with azide until paraffin embedding. Tissue was embedded using a Tis-
sue-Tek Vacuum Infiltration Processor 6 (Sakura Finetek, Torrance, CA, USA). Thereafter,
2 μm sections were cut on a HM 355S Automatic Microtome (Thermo Scientific) microtome.
Immunohistochemical staining of tissue for microscopy
Immunohistochemical staining of formalin fixed paraffin embedded tissue was done as
described in detail previously [35]. Briefly, sections were rehydrated from xylene through
graded ethanol solutions into water and subsequently boiled in TEG buffer (10 mM Tris, 0.5
mM EGTA, pH = 9.0) for heat induced antigen retrieval using. Endogenous peroxidases and
free aldehyde groups were blocked by addition of 0.6% hydrogen peroxide (H2O2) and 50 mM
NH4Cl into PBS followed by overnight incubation at 4˚C with rabbit anti-eGFP antibodies
(A6455, Invitrogen) (0.1% Triton X100 in PBS). After washing, sections were incubated with
horseradish peroxidase-conjugated secondary antibodies (DakoCytomation) and visualized
using the Liquid DAB+ Substrate Chromogen System (3,3’-Diaminobenzidine, K3467, Dako-
Cytomation) or using Alexa fluorophore-conjugated secondary antibodies (Molecular Probes,
Eugene, OR) for fluorescence labeling. Sections subjected to 3,3’-Diaminobenzidine depen-
dent labeling were counterstained with hematoxylin.
For histological evaluation of changes in renal morphology following AngII-infusion, sec-
tions were rehydrated to 70% ethanol and stained with Mayers Hematoxylin before being
dehydrated and mounted.
Statistical analyses
Data are presented as mean ± SEM. T-test was used for comparison between two groups,
including analysis of blood pressure and heart rate at baseline. Development of hypertension
and heart rate in response to AngII infusion were analysed with two-way ANOVA with a post-
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hoc Bonferroni’s multiple comparisons test. Analyses of myograph experiments were done
using one- or two-way ANOVA with Bonferroni’s multiple comparisons test. All tests were
performed via the GraphPad Prism statistics program (version 6.0). Values were considered
significant with p<0.05. In case of a skewed distribution, logarithmic values were used.
Results
Evaluation of Nr3c2 excision in mouse endothelial cells
To validate that expression of the Nr3c2 gene encoding the MR was reduced in endothelial cells
of EC-MR KO mice, we isolated endothelial cells from the aorta of EC-MR KO and WT litter-
mates. Expression analysis of Nr3c2 in endothelial isolates as evaluated by semi-quantitative
PCR, revealed a significantly reduced expression of Nr3c2 gene in samples obtained from
EC-MR KO mice (Fig 1A). To investigate in detail whether Cre activity would lead to deletion
of the Nr3c2 gene in select vascular beds, we isolated thoracic aortas, renal arteries, and mesen-
teric arteries from EC-MR KO and WT mice after perfusion with phosphate buffered saline (Fig
1B). Given that exon 3 of the Nr3c2 is floxed in this model [26], PCR amplification of mRNA
transcribed from the Nr3c2 gene, using a primer set spanning exons 2–4, would yield a single
fragment corresponding in size to 253 bp in both Nr3c2 floxed mice not expressing the Tie2-Cre
driven recombinase and Nr3c2 floxed mice expressing the Tie2-Cre transgene. Furthermore, if
the given endothelial cell expresses the floxed Nr3c2 gene as well as the Cre recombinase driven
by Tie2, amplification of another shorter mRNA product lacking exon 3, corresponding in size
to 113 bp will also be present in these animals (Fig 1B). As can be observed, a shorter fragment
could be identified in all vessels investigated only in the EC-MR KO mice (Fig 1B).
In an effort to determine which subpopulations of endothelial cells in kidney were expressing
the Tie2-Cre recombinase and hence able to inactivate the floxed Nr3c2 gene, the Tie2-Cre strain
was intercrossed with Z/EG reporter mice. The Z/EGmouse expresses eGFP when sufficient Cre
activity is present in the cell. Immunohistochemical analysis showed eGFP expressing cells in all
endothelial compartments within kidney, ranging from larger renal vessels, afferent arterioles,
peritubular capillaries to vasa recta bundles (Fig 1C–1E), suggesting that if an endothelial cell
express the Nr3c2 gene product, Cre recombinase mediated knockout is likely to occur.
Measurements of mean arterial pressure in EC-MR KO and WT mice
Mean arterial pressure (MAP) and heart hate (HR) was measured at baseline and in two experi-
mental settings with EC-MR KO mice and WT receiving continuous intravenous infusions of
AngII at dosages of 60 ng/kg/min or 100 ng/kg/min. The groups of mice receiving 100 ng/kg/min
showed an increased mortality during infusion, and therefore the dosage was lowered to 60 ng/
kg/min. Measurements of MAP during baseline showed no changes in blood pressure, neither
when analysed by evaluation of average blood pressures (p = 0.14) nor area under curve (p = 0.49)
(Fig 2A). Changes in HR may aid in stabilizing blood pressure via compensatory reductions in
beat frequency, however no changes between the EC-MR KO and WT mice could be detected at
baseline (Fig 2B). AngII infusion dose dependently increased MAP in both EC-MR KO and WT
mice. The effect of 60 ng/kg/min AngII infusion on alterations in MAP was not different between
EC-MR KO and WT mice (Fig 2C). Heart rate also did not differ between genotypes (Fig 2D).
Similar findings were obtained with infusion of 100 ng/kg/min of AngII (Fig 2E & 2F).
EC-MR deletion does not alter contractility or relaxation of the renal artery
Myographic recording of vessel wall tension were used to evaluate contraction and relaxation
responses of the renal artery to the thromboxane analog U46619, acetylcholine and sodium
Mineralocorticoid receptors in renal vasculature
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Fig 1. Evaluation of Nr3c2 excision in endothelial mineralocorticoid receptor knockout mice (EC-MR KO) and in littermate controls (WT). Expression of mRNA
of Nr3c2 from isolated aortic endothelial cells in EC-MR KO and WT mice (n = 6 per group). (B) Expression of mRNA from the abdominal aorta, mesenteric artery and
renal artery. Amplification of mRNA transcribed from the Nr3c2 gene using a primer set spanning exons 2–4 would yield only one fragment of 253 bp in mice carrying
the floxed Nr3c2 alleles, whereas mice expressing both the floxed Nr3c2 gene as well as the Cre recombinase driven by Tie2 promoter would yield another fragment of 113
bp. (C-E) Immunohistochemical analysis of kidney from intercrosses of mice expressing Tie2-Cre and the LacZ/eGFP reporter gene (Z/EG). eGFP expression is detected
in cells positive for Cre recombinase. (C) Cre-dependent excision allowing eGFP expression can be detected in arterioles within kidney (denoted A). (D) eGFP positive
Mineralocorticoid receptors in renal vasculature
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nitroprusside (SNP). Renal arteries were isolated from EC-MR KO and WT mice before or
after subcutaneous infusion of AngII for 2 or 4 weeks by osmotic minipumps, delivering the
drug at a dose of 1000 ng/kg/min. Changes in contractility were subsequently analyzed in
cells were also present in the renal microvasculature, in the vasa recta bundels in the outer medulla (indicated by arrows) and (E) afferent arterioles (AA) located adjacent
to the macula densa (MD), in glomerular (G) endothelial cells lining the capillary loops as well as the peritubular capillaries (indicated by arrows).
https://doi.org/10.1371/journal.pone.0193032.g001
Fig 2. Evaluation of mean arterial pressure (MAP) and heart rate (HR) between wildtype WT and EC-MR KO during baseline and AngII infusion. Baseline (A)
MAP and (B) HR were measured (D1-N3) in EC-MR KO and WT mice (n = 14–18 per group). (C) MAP and (D) HR were measured for 7 days (D3-D10) after start of
AngII infusion (60 ng/kg/min) (n = 7–9 per group). (E) MAP and (F) HR were also measured for 4 days (D4-D7) after infusion of angiotensin II (AngII 100 ng/kg/min)
(n = 7–9 per group). All data are mean ± SEM.
https://doi.org/10.1371/journal.pone.0193032.g002
Mineralocorticoid receptors in renal vasculature
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response to increasing concentrations of the thromboxane analog U46619. No changes in con-
tractility could be observed after application of increasing amounts of U46619 during baseline
and after 2 or 4 weeks of AngII infusion in WT mice (Fig 3). The EC-MR KO mice displayed a
similar contractile response to U46619 as WT both during baseline (Fig 3A), after 2 weeks of
Fig 3. Determination of contractility and endothelial function in the renal artery in WT and EC-MR KO mice. Effect on contraction to the thromboxane analog
U46619 of (A) WT and EC-MR KO at baseline (n = 8–12 per group), (B) WT and EC-MR KO after 2 weeks of angiotensin II (AngII) infusion (n = 7–8 per group) and
(C) WT and EC-MR KO after 4 weeks of AngII infusion (n = 11–7 per group). Effect on acetylcholine (Ach)-induced endothelial-dependent relaxation of renal arteries
from WT and EC-MR KO at baseline (n = 7–11 per group), (E) WT and EC-MR KO after 2 weeks of AngII infusion (n = 7–8 per group), and (F) WT and EC-MR KO
after 4 weeks of AngII infusion (n = 11–7 per group). Effect on endothelial-independent relaxation by the NO donor, sodium nitroprusside (SNP) in (G) WT and EC-MR
KO at baseline (n = 7–11 per group), (H) WT and EC-MR KO after 2 weeks of AngII infusion (n = 7–8 per group), and (I) WT and EC-MR KO after 4 weeks of AngII
infusion (n = 11–7 per group). All data are mean ± SEM.
https://doi.org/10.1371/journal.pone.0193032.g003
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AngII infusion (Fig 3B), and after 4 weeks of AngII infusion (Fig 3C). Endothelial-dependent
vessel relaxation was measured in renal arteries from WT and EC-MR KO mice using acetyl-
choline. Application of increasing concentrations of acetylcholine in the presence of U46619
at the dosage leading to 70% of precontraction values, resulted in dose-dependent dilatation of
the renal arteries. No change in the vasorelaxation actions of acetylcholine was observed
between WT and EC-MR KO mice both at baseline or following 2 or 4 weeks of AngII infu-
sion. Impaired endothelial-derived responses to acetylcholine (10−7 M) were observed after 4
weeks of AngII infusion in both genotypes, in comparison to that observed at baseline (S1
Fig), suggesting the development of endothelial dysfunction after prolonged AngII-infusion.
However, there was no difference in relaxation of the renal artery between the WT and
EC-MR KO at baseline (Fig 3D), after 2 weeks of AngII infusion (Fig 3E), or after 4 weeks of
AngII infusion (Fig 3F). The nitric oxide (NO) donor sodium nitroprusside (SNP) was used to
evaluate endothelium-independent relaxation of the renal artery. Again, contractile changes
were assessed in the presence of U46619 at the dosage leading to 70% contraction of the vessel.
No differences were noted in either genotype in response to SNP mediated dilatation of the
renal arteries (Fig 3G–3I). In brief, these observations suggest that the MR in EC in renal arter-
ies does not augment vessel contractility, nor play a role in development of endothelial
dysfunction.
No change in the contractility of afferent arterioles or effective renal
plasma flow between EC-MR KO and WT mice
Chronic aldosterone exposure has previously been shown to inhibit NO-mediated dilatation
(secondary dilatation after K+ induced constriction) of afferent arterioles [12]. We therefore
sought to evaluate whether endothelial MR deletion would affect the function of renal resis-
tance vessels by measuring changes in luminal diameter in perfused microdissected afferent
arterioles. Depolarization-induced vasoconstriction (100 mM K+ solution) did not show sig-
nificant changes between EC-MR KO and WT mice (Fig 4A). Secondary dilatory responses
also remained unaltered between the two groups of mice (Fig 4B). Moreover, no change was
observed in response to increasing concentrations of acetylcholine (10−9 M to 10−6 M).
We also attempted to investigate contractile changes in afferent arterioles isolated from
mice receiving AngII infusion for 2 weeks, however technically this proved difficult, due to the
strong constrictor response of AngII. To evaluate whether deletion of the endothelial MR may
change renal plasma flow (RPF), para-aminohippurate clearance was measured during base-
line and following 7-day infusion of 60 ng/kg/min of Ang II and the effective RPF was deter-
mined. At baseline, no change could be observed in effective RPF between the EC-MR KO and
WT mice (Fig 4C). Infusion of AngII resulted in a mean increase in effective RPF from 0.49
ml/min/25g mouse to a mean of 1.15 ml/min/25g mouse. No differences could be observed
between the EC-MR KO and WT mice either before or after infusion of AngII (Fig 4C).
Evaluation of renal function in mice EC-MR KO and WT mice undergoing
4 weeks of AngII infusion
We also wanted to investigate, whether EC MR may elicit alterations in estimated eGFR and
urinary Na+ rates between EC-MR KO and WT mice undergoing AngII infusion for 4 weeks.
After 4 weeks of AngII infusion animals were placed in metabolic cages for acclimatization
and thereafter, creatinine clearance as well as urinary Na+ excretion rates were measured for
24 hours. Water and food intake did not differ between EC-MR KO and WT mice (Fig 5A and
5B). Similarly, urinary volume remained unchanged (Fig 5C). Furthermore, neither serum
Na+ nor urinary Na+ excretion was altered during AngII infusion between the two genotypes
Mineralocorticoid receptors in renal vasculature
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(Fig 5D and 5E). Finally, neither estimated GFR as determined by creatinine clearance (Fig
5F) nor the fractional excretion of Na+ (FENa, Fig 5G) differed between groups following 4
weeks of AngII infusion. Furthermore, No change in Na+/ K+ ratio could be detected between
groups (Fig 5H).
To evaluate whether EC-MR KO mice would be protected from renal damage following 4
weeks of AngII infusion, urinary albumin excretion, tubular and glomerular histology as well
Fig 4. Vascular response of afferent arterioles and renal plasma flow (RPF) of WT and EC-MR KO mice. (A) Depolarized-induced vasoconstriction to 100 mM K+
solution of WT and EC-MR KO (n = 6–5 per group). (B) Secondary dilatory responses of afferent arterioles of WT and EC-MR KO (n = 6–5 per group). (C) Effective
RPF calculated from para-aminohippurate clearance before and after 60 ng/kg/min infusion of angiotensin II (AngII) of WT and EC-MR KO (n = 5–7 per group).
https://doi.org/10.1371/journal.pone.0193032.g004
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as peritubular density was analyzed. No change was apparent in 24-hour urinary albumin
excretion as well as in the albumin/creatinine ratio between EC-MR KO and WT mice (Fig
6A). The histopathological changes were evaluated using PAS stained sections, and changes
were scarce. The overall structure of the kidneys was normal without hydronephrosis. In both
groups, the glomeruli were normal without sclerosis or hypercellularity. Minor focal areas
with tubular dilatation and presence of hyaline casts were noted, and some perivascular
inflammation was present, mainly around extrarenal branches of the renal artery within both
genotypes after AngII infusion for 4 weeks. In one KO mouse the larger arteries showed inti-
mal thickening and some inflammation together with perivascular inflammation. One WT
mouse had more chronic intimal thickening and one a few small extrarenal arteries with
thrombosis. (Fig 6B and 6C).
Discussion
The current study delineates in detail the effects of MR deletion in EC on renal vessel reactivity
and renal function. Overall, our data suggest that the MR in EC does not play a role in altering
contractility of the renal arteries during conditions as endothelial dysfunction, nor does it con-
tribute to changes in renal function or hemodynamics. These conclusions can be drawn from
the following observations. i) MR deletion in EC does not modify pressure at baseline or in
Fig 5. Evaluation of renal function and Na+ handling. Renal function was evaluated in WT and EC-MR KO after 4 weeks of angiotensin II infusion by osmotic
minipumps (1000 ng/kg/min) in metabolic cages. (A) Water intake, (B) Food intake, (C) urine volume, (D) serum Na+ concentration, (E) Urinary Na+ excretion, (F)
estimated glomerular filtration rate determined by creatinine clearance, (G) fractional excretion of Na+. (H) Urinary Na+/ K+ ratio (n = 8 per group). All data are
mean ± SEM.
https://doi.org/10.1371/journal.pone.0193032.g005
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Fig 6. Evaluation of renal damage. Renal damage was evaluated following 4 weeks of angiotensin II (AngII) infusion
by osmotic minipumps (1000 ng/kg/min) in metabolic cages. (A) Albumin/creatinine ratio between WT and EC-MR
KO littermates (n = 8 per group). (B-C) Histopathological changes evaluated by PAS staining in WT and EC-MR KO
mice after 4 weeks of AngII infusion. (B) Evaluation of histopathological changes between WT and EC-MR KO were
Mineralocorticoid receptors in renal vasculature
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response to AngII. ii) Renal artery vasodilatory responses to acetylcholine do not differ
between EC-MR KO and WT mice, neither at baseline nor after 2 or 4 weeks of AngII infu-
sion. iii) No change in contractility of afferent arterioles was noted in EC-MR KO and WT
mice and iv) effective RPF was not affected at baseline or following AngII infusion between the
genotypes. v) Urinary Na+ handling and estimated eGFR does not differ between genotypes
after 4 weeks of AngII infusion. vi) No change in urinary albumin excretion or histopatholog-
ical changes were noted between the genotypes.
Deletion of the EC MR does not affect relaxation or constriction during basal conditions in
aorta and mesenteric arteries [21, 22]. Mueller et al, have shown that the EC-MR is involved in
vasoconstriction in select vascular beds and this constriction is also dependent on the specific
contractile agonist employed. Specifically, they found that the constriction of the coronary
arterioles to U44619 was lower in the EC-MR KO mice in the basal state, which was not found
in mesenteric arterioles [23]. This evidence points towards diverse roles for the EC MR in vari-
ous vascular beds and vessel types. Heterogeneity of endothelium-dependent responses
between different vascular beds are well-known (e.g. [36]). Classical examples are the response
to acetylcholine in canine blood vessels where endothelium-dependent relaxations occur in
most vessels tested, while endothelium-independent contractions are found in cerebral arteries
[37], or the presence of endothelium-dependent relaxations to vasopressin in cerebral, but not
in peripheral arteries [38]. Differences between vascular beds may rely on the amount of MR
expression as well as downstream signalling mediators utilized by the MR.
Recent studies examining MR function in various vascular beds in experimental models
with endothelial dysfunction, hypertension and/or high circulating aldosterone concentra-
tions, clearly suggest that not all vascular beds show altered vessel contractility in response to
deletion of the EC MR [21–23]. For instance, aldosterone- or DOCA/salt-induced endothelial
dysfunction did not affect vessel contraction in the aorta and mesenteric arteries from EC-MR
KO mice in comparison to WT mice [21, 22]. In contrast, AngII-induced hypertension
resulted in contraction-dependent alterations in vessel function in the coronary arterioles
alone, and not the mesenteric vessels [23]. The absence of protective effects on renal artery
contractility upon EC MR deletion may be understood in light of these divergent findings in
various vascular beds.
In the current study we found no change in baseline blood pressure between EC-MR KO
and WT mice, either at baseline or following AngII infusion. The lack of change is in line with
previous studies investigating the effects of EC MR deletion on blood pressure maintenance
[22, 23]. Overall, these observations suggest that the EC MR does not contribute to blood pres-
sure maintenance in basal states and following experimental hypertensive models. However,
overexpression of the MR in the EC of mice does promote an increase in blood pressure [10].
Here, EC dependent overexpression of the MR promotes an increase in blood pressure, likely
resulting from an exaggerated myogenic response. Therefore, it is possible that MR activation
may lead to altered contractility, which could facilitate the development of hypertension. How-
ever, it is unclear whether these MR EC overexpressors inappropriately express the MR in
endothelia normally devoid of the MR.
In our model, the EC-MR KO did not protect against contraction of the renal artery, nei-
ther at baseline nor after 2 or 4 weeks of AngII infusion. Furthermore, our data suggest that
deletion of the MR in EC during baseline and in conditions of hypertension and endothelial
dysfunction does not affect overall acetylcholine-induced endothelium dependent responses,
determined using PAS stained kidney crossections. Overall, no marked changes in structure could be seen between
genotypes.
https://doi.org/10.1371/journal.pone.0193032.g006
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and likely the bioavailability of NO in renal arteries. However, these responses may also differ
between vascular beds. For instance, as reported by Rickard et al, deletion of the MR in EC was
protective against the development of endothelial dysfunction as evaluated by acetylcholine-
dependent endothelial responses in aorta, but not in mesentery [22]. These data suggests that
the effect of the MR in the EC may act on differing hitherto unknown molecular mechanisms,
depending on the vascular beds. Interestingly, mice overexpressing the MR in endothelial cells
show an increased response to constrictors such as U46619 in mesenteric vessels, while no dif-
ference in endothelial-dependent acetylcholine response could be observed [10]. Moreover,
most pronounced effects of EC MR deletion seems to be reported in conditions of endothelial
dysfunction, rather than during basal conditions [21–23]. This may result from the observa-
tion that abundance in endothelium is much lower than renal tubular epithelial cells, suggest-
ing the EC MR may be less responsive to physiological circulating levels of aldosterone, while
primarily activated during conditions of high circulating aldosterone. However, these effects
were not observed in this study of the vasculature of the renal artery.
No changes in vessel function could be observed in afferent arterioles. Being the major
resistance vessel in kidney, this would play an important role in regulating renal blood flow.
As such, no changes could be found in blood flow in the basal state between the genotype, sug-
gesting that the EC MR does not contribute to regulating flow under normal physiological
conditions. However, we have previously shown that aldosterone have an acute effect on affer-
ent renal vessels, by inhibiting depolarization-induced vasoconstriction [12]. This beneficial
effect occurs after application of aldosterone concentrations found in the low physiological
range and is blocked by MR antagonists. Hence, multiple effects of aldosterone may modulate
vessel function during various physiological and pathophysiological settings. Thus, aldosterone
may exert acute stimulatory effect on vessel function, while chronically high levels would lead
to the pathological effects [12]. Similar observations of acute aldosterone effects have been
made in aortic rings [39]. Infusion of AngII resulted in an increase in effective renal plasma
flow, while no differences could be observed between the WT and EC-MR KO mice. The
increase in effective RPF following AngII infusion is in line with previous observations from
Casare et al. who find that long term infusion of AngII increase RPF [40] and a concomitant
decrease in renal vascular resistances. This increase in RPF may result from an impairment of
renal auto-regulation following long-term blood pressure elevation. Given the technical diffi-
culties we had in measuring afferent arteriole function following chronic AngII infusion in
mice, we do not know whether long-term administration could affect vessel function differ-
ently, than in the EC-MR knockout mice.
Given the strong constrictor effects of AngII, one would predict that in states of endothelial
dysfunction, as induced by 4 weeks of AngII infusion in our study, and in response to vasocon-
strictors such as AngII itself, could yield alterations between the genotypes in urinary Na+
excretion and GFR. Such alterations could be elicited as modulation of renal artery resistance
would alter the pressure-natriuresis relationship, and thereby impair the kidneys ability to ade-
quately sense blood pressure akin to renal artery stenosis. Our model does not show such
changes in urinary Na+ excretion and GFR, which could be due to a variety of reasons, but
may potentially result from the strong constrictor response already elicited by infusion of
supraphysiological AngII dosages, contracting the arteries of WT and EC-MR KO to the same
extend in vitro. However, the observed differences in contractility and relaxation between dif-
ferent vascular beds could influence the function of the EC MR in vivo in conditions with
endothelial dysfunction and a less potent constrictor milieu.
It is therefore speculated, that the effect of the EC MR differs depending on the type of vas-
culature and the organs being investigated. The role of the EC-MR in protecting against patho-
physiological changes seems much more pronounced in the heart, where deletion of the EC
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MR attenuated development of cardiac injury. However, in the kidney, MR deletion in the EC
did not affect the development of renal injury [41]. This is in line with previous studies of the
aorta, where EC MR deletion protected against development of endothelial dysfunction [22,
42], while we did not observe any effect of EC MR deletion on the renal artery after 4 weeks of
AngII infusion, nor any differences in albuminuria, or renal Na+ handling. The beneficial
effect of pharmacologic antagonism of the MR on the kidney could also stem from blockade of
the MR in the smooth muscle cells, rather than MR in EC. In fact, conditional deletion of the
Nr3c2 gene in smooth muscle cells protected against renal injury in an ischemia-reperfusion
model, while the knockout of the MR in EC did not affect the injury [43].
This study investigated in detail the effect of the EC MR on the renal vasculature. We found
no effect of EC-MR deletion on development of hypertension, development of endothelial dys-
function in the renal artery, or any alterations in RPF and afferent arteriole contractility or
overall renal function and morphology. It therefore appears that the EC MR only plays a
minor role in renal physiological mechanisms, nor is protective against pathological changes
in kidney and renal vasculature, in models of experimental hypertension and endothelial
dysfunction.
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